Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region

BACKGROUND: With emerging evidence on the efficacy of adding dapagliflozin to standard care for patients with heart failure with reduced ejection fraction (HFrEF), this study assessed the cost-effectiveness of add-on dapagliflozin to standard care versus standard care alone for HFrEF from the perspe...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Chia-Te, Yang, Chun-Ting, Toh, Han Siong, Chang, Wei-Ting, Chang, Hung-Yu, Kuo, Fang-Hsiu, Lee, Mei-Chuan, Hua, Yi-Ming, Tang, Hsin-Ju, Strong, Carol, Ou, Huang-Tz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502298/
https://www.ncbi.nlm.nih.gov/pubmed/34627231
http://dx.doi.org/10.1186/s12933-021-01387-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502298/
https://www.ncbi.nlm.nih.gov/pubmed/34627231
http://dx.doi.org/10.1186/s12933-021-01387-3

Ejemplares similares